CML-CAB 2017
2nd CML-CAB: Frankfurt, Germany, 24-26 February 2017
On 25-26 February 2017, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, has hosted its second meeting to discuss issues of major concern to the CML community.
CML-CAB Members attending the 2nd CML-CAB as patient experts
The CML Advocates Network was represented by expert patient advocates from all world regions:
- Jan Geissler, Germany (Co-chair)
- Giora Sharf, Israel (Co-chair)
- Jana Pelouchova, Czech Republic
- Mercedes Arteaga, (representing Latin America)
- Gail Sperling, USA (representing North America)
- Bahija Gouimi, Morocco (representing Africa and Middle East)
- Rita Christensen, Denmark (representing Western Europe)
- Jelena Cugurovic, Serbia (representing Eastern Europe)
- Rod Padua, Philippines (representing East Asia and Pacific)
- Felice Bombaci, Italy (Western Europe)
- Cornelia Borowczak, Germany (Western Europe)
- Yair Bar David, Israel (Middle East)
- Parameswaran Puthen, India (East Asia / Pacific)
- Ferdinand Micho, Kenya (Africa)
- Silvia Castillo De Armas, Guatemala (Latin America)
- Sarunas Narbutas, Lithuania (Eastern Europe)
Plus the CML Advocates Network team:
- Lidija Pecova (Programme Manager)
- Celia Marin (Programme Manager)
CML-CAB with Novartis, 26 Feb 2017, 8:00-15:30
The following topics were discussed during the CML-CAB:
- Presentation and Discussion: Clinical Development
- Presentation and Discussion: Patient-Reported Outcomes
- Presentation and Discussion: CML Today and Tomorrow
- Presentation and Discussion: TFR Communication & Educational Materials
- Discussion: Dialogue and Next Steps
Non-confidential minutes of the meeting are available to CML Advocates Network members here. Please log in on the website with your memership account, and then download the file here. Link will not work if you are not logged in!
CML-CAB with Takeda and Incyte, 25 Feb 2017, 14:00-18:00
The following topics were discussed during the CML-CAB:
- Takeda, ARIAD and Incyte
- Presentation and Discussion: Clinical Development
- Access to Ponatinib
- Collaboration
- Next Steps
Non-confidential minutes of the meeting are available to CML Advocates Network members here. Please log in on the website with your memership account, and then download the file here. Link will not work if you are not logged in!
For more information, please contact the CML-CAB co-chair Jan Geissler <>
